Jasper Therapeutics Inc (JSPR)
Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
Industry • Biotechnology & Pharmaceuticals |
Sector • Healthcare |
News
Jasper Therapeutics Induces Employee Engagement with Stock Option Grants
Jasper Therapeutics: Revolutionary Antibody Therapy and Stock Split Point to Promising Future
JSPR experiences disturbing decline in corporate performance during latest fiscal period
Jasper Therapeutics Inc Reports Larger Shortfall in Q2 2023 Despite Positive Market Performance
The company published Revenue of $0.507 millions, in the October to December 31 2022
The company declared operating loss in the third quarter of 2022
reported Revenue of $0.625 million, in the Jun 30 2022 report
Top-line was $4.593 million at the company in most recent fiscal period